首页> 外文会议>ASMS Conference on Mass Spectrometry and Allied Topics >Determination of EGFR and VEGF signaling pathway activity by immuno-MALDI to predict the outcome of targeted colorectal cancer (CRC) treatment
【24h】

Determination of EGFR and VEGF signaling pathway activity by immuno-MALDI to predict the outcome of targeted colorectal cancer (CRC) treatment

机译:免疫马尔迪的EGFR和VEGF信号通路活性预测靶向结直肠癌(CRC)治疗的结果

获取原文

摘要

iMALDI assays for quantifying AKT1 and AKT2 from tissue samples have been developed. The next steps include assay validation (precision, linearity, recovery), as well as analysis of mouse xenograft models, breast cancer and CRC tissue samples. Data will be integrated with genomics data measured at the Segal Cancer Center, Montreal, and changes in molecular patterns, as well as patient outcome in response to targeted treatment will be examined.
机译:已经开发出来自组织样品的用于量化AKT1和AKT2的iMALDI测定。下一步包括测定验证(精确,线性,恢复),以及小鼠异种移植模型,乳腺癌和CRC组织样品的分析。数据将与在Segal癌症中心,蒙特利尔和分子模式的变化中进行的基因组学数据集成,以及患有针对靶向治疗的患者结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号